Skip to main content
SpringerLink
Log in

NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers

  • Chapter
  • First Online:
Non-Alcoholic Fatty Liver Disease

Abstract

Nonalcoholic fatty liver disease (NAFLD) is becoming a major cause of hepatocellular carcinoma (HCC), with a steadily rising trend compared to viral or alcohol-induced chronic hepatitis. The large burden of the underlying liver disease, the chance of HCC arising in the absence of cirrhosis, and the incomplete knowledge of the mechanisms leading to carcinogenesis in NAFLD hampers the development of markers for targeting subjects at high risk and contributes to impede an effective care of patients with HCC. Hence, poor surveillance has prevented the development of an adequate treatment for NAFLD-related HCC. Systemic and hepatic molecular mechanisms involved in hepatocarcinogenesis as well as potential early markers of HCC are being extensively investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

    Article  PubMed  Google Scholar 

  2. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.

    Article  PubMed  Google Scholar 

  3. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755–65.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Setiawan VW, Lim U, Loren L, et al. Sex and ethnic differences in the association of obesity with risk of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2016;14(2):309–16.

    Article  PubMed  Google Scholar 

  6. Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645–57.

    Article  CAS  PubMed  Google Scholar 

  7. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369–80.

    Article  PubMed  Google Scholar 

  8. Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013;108:222–8.

    Article  CAS  PubMed  Google Scholar 

  9. Krawczyk M, Stokes CS, Romeo S, Lammert F. HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J Hepatol. 2015;62:980–1.

    Article  CAS  PubMed  Google Scholar 

  10. Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–19.

    Article  PubMed  Google Scholar 

  11. Agrawal S, Agarwal S, Arnason T, et al. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015;13(7):1221–30.

    Article  PubMed  Google Scholar 

  12. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698–705.

    Article  PubMed  Google Scholar 

  13. Mohamad B, Shah V, Onyshchenko M, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int. 2016;10(4):632–9.

    Article  PubMed  Google Scholar 

  14. Stoot JH, Coelen RJ, De Jong MC, et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12:509–22.

    Article  Google Scholar 

  15. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology. 2014;59:2188–95.

    Article  PubMed  Google Scholar 

  16. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.

    Article  CAS  PubMed  Google Scholar 

  17. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30.

    Article  CAS  PubMed  Google Scholar 

  18. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.

    Article  PubMed  Google Scholar 

  19. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–9.

    Article  PubMed  Google Scholar 

  20. Oda K, Uto H, Matawari S, et al. Clinical features of hepatocellular carcinoma associated with non-alcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1–9.

    Article  PubMed  Google Scholar 

  21. Berentzen TL, Gamborg M, Holst C, et al. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol. 2014;60(2):325–30.

    Article  PubMed  Google Scholar 

  22. Hassan MM, Abdel-Wahab R, Kaseb A, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149(1):119–29.

    Article  PubMed  Google Scholar 

  23. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49:851–9.

    Article  PubMed  Google Scholar 

  24. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–31.

    Article  CAS  PubMed  Google Scholar 

  25. Salomao MS, Yu WM, Brown RS, et al. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630–6.

    PubMed  Google Scholar 

  26. Vanni E, Bugianesi E. Obesity and liver cancer. Clin Liver Dis. 2014;18:191–203.

    Article  PubMed  Google Scholar 

  27. Ip BC, Liu C, Smith DE, et al. High-refined-carbohydrate and high-fat diets induce comparable hepatic tumorigenesis in male mice. J Nutr. 2014;144:647–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vos M, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013;57:2525–31.

    Article  CAS  PubMed  Google Scholar 

  29. Piscaglia F, Svegliati-Baroni G, Barchetti A, HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–38.

    Article  PubMed  Google Scholar 

  30. Mittal S, Sada Y, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–60.

    Article  PubMed  Google Scholar 

  31. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci. 2015;60(10):3142–8.

    Article  CAS  PubMed  Google Scholar 

  32. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.

    Article  Google Scholar 

  33. Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  PubMed  Google Scholar 

  34. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70.

    Article  PubMed  Google Scholar 

  35. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

  36. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res. 2012;5:1124–30.

    Article  Google Scholar 

  37. Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384–98.

    Article  PubMed  Google Scholar 

  38. Wen CP, Lin J, Yang CY, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012;104:1599–611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mousa SA, Aljada A. Metformin and neoplasia: implications and indications. Pharmacol Ther. 2011;133(1):108–15.

    PubMed  Google Scholar 

  40. Zhang H, Gao C, Fang L, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013;48:78–87.

    Article  CAS  PubMed  Google Scholar 

  41. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011;26:858–65.

    Article  PubMed  CAS  Google Scholar 

  42. Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323–32.

    Article  CAS  PubMed  Google Scholar 

  43. Kurmann A, Wanner B, Martens F, et al. Hepatic steatosis is associated with surgical-site infection after hepatic and colorectal surgery. Surgery. 2014;156:109–16.

    Article  PubMed  Google Scholar 

  44. Wong R, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.

    Article  PubMed  Google Scholar 

  45. Safwan M, Collins KM, Abouljoud MS, et al. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 2018;23(11):1415–21.

    Article  Google Scholar 

  46. Wang X, Li J, Riaz DR. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(3):394–402.

    Article  PubMed  Google Scholar 

  47. Rubenstein JH, Morgenstern H, McConell D, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus. Gastroenterology. 2013;145(6):1237–44.e1–e5. https://doi.org/10.1053/j.gastro.2013.08.052.

    Article  CAS  PubMed  Google Scholar 

  48. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg. 2008;247(6):909–15. https://doi.org/10.1097/SLA.0b013e3181612cac.

    Article  PubMed  Google Scholar 

  49. Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(13):2241–2255.e4. 10.1016/j.cgh.2015.06.041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Francois F, Roper J, Goodman AJ, et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut. 2008;57(1):16–24. https://doi.org/10.1136/gut.2007.131672.

    Article  CAS  PubMed  Google Scholar 

  51. Kendall BJ, Macdonald GA, Hayward NK, et al. Leptin and the risk of Barrett’s oesophagus. Gut. 2008;57(4):448–54. https://doi.org/10.1136/gut.2007.131243.

    Article  CAS  PubMed  Google Scholar 

  52. Garcia JM, Splenser AE, Kramer J, et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett’s esophagus: a case-control study. Clin Gastroenterol Hepatol, 2014. 12(2):229–238.e3. https://doi.org/10.1016/j.cgh.2013.07.038.

  53. Chen D-C, Chung Y-F, Yeh Y-T, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237(1):109–14. https://doi.org/10.1016/j.canlet.2005.05.047.

    Article  CAS  PubMed  Google Scholar 

  54. Caldefie-Chézet F, Dubois V, Delort L, Rossary A, Vasson M-P. [Leptin: Involvement in the pathophysiology of breast cancer]. Ann Endocrinol (Paris). 2013;74(2):90–101. https://doi.org/10.1016/j.ando.2013.03.005.

  55. Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev. 2009;10(6):660–70. https://doi.org/10.1111/j.1467-789X.2009.00592.x.

    Article  CAS  PubMed  Google Scholar 

  56. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12. https://doi.org/10.1038/35053000.

    Article  CAS  PubMed  Google Scholar 

  57. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300(2):472–6. http://www.ncbi.nlm.nih.gov/pubmed/12504108. Accessed 21 Feb 2016.

    Article  CAS  PubMed  Google Scholar 

  58. Codoñer-Franch P, Alonso-Iglesias E. Resistin: insulin resistance to malignancy. Clin Chim Acta. 2015;438:46–54. https://doi.org/10.1016/j.cca.2014.07.043.

    Article  CAS  PubMed  Google Scholar 

  59. Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133(2):157–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy

    Ramy Younes

  2. Department of Medical Sciences, Division of Gastroentrology and Hepatology, University of Turin, Turin, Italy

    Elisabetta Bugianesi

Authors
  1. Ramy Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabetta Bugianesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabetta Bugianesi .

Editor information

Editors and Affiliations

  1. Department of Medical Sciences, Division of Gastroentrology and Hepatology, University of Turin, Turin, Italy

    Elisabetta Bugianesi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Younes, R., Bugianesi, E. (2020). NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers. In: Bugianesi, E. (eds) Non-Alcoholic Fatty Liver Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-95828-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95828-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95827-9

  • Online ISBN: 978-3-319-95828-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation